Advanced visualization software developer Imaging Biometrics is highlighting a recent study that used its IB Neuro and IB Delta Suite software to quantify the dynamic susceptibility contrast (DSC) MR perfusion imaging exams of patients with brain tumors.
For the study, first author Kathleen Schmainda, PhD, from the Medical College of Wisconsin and colleagues acquired the data of 84 patients with brain tumors who underwent a DSC MR perfusion exam with either a single dose of gadobutrol contrast (Gadavist, Bayer HealthCare) and a lower-flip angle or the more common double-dose, or preload, method. Then they used Imaging Biometrics' IB Neuro and IB Delta Suite software to generate quantitative perfusion relative cerebral blood volume (rCBV) maps.
The researchers found no statistically significant difference between the rCBV values obtained using the single- and double-dose protocols. In addition, they found that automating image intensity calibration for the rCBV data using IB Neuro technology resulted in even better and less variable agreement between the single- and double-dose methods (American Journal of Neuroradiology, March 28, 2019).
"The ability to obtain comparable rCBV measurements with up to 50% less contrast agent is a step toward addressing concerns regarding the use of suprastandard (> 0.1 mmol/kg) contrast agent dosing," the authors wrote. "This is important due to recent restrictions imposed by the [U.S. Food and Drug Administration] on the use of gadolinium-based contrast agents."
